There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 1 | 3 | 7850.5 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| Ask | Qty | Orders |
|---|---|---|
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
Annual Revenue,rose 14.76%, in the last year to ₹21,994.3 Cr. Its sector's average revenue growth for the last fiscal year was 16.1%.Annual Net Profit,rose 60.91% in the last year to ₹1,445.9 Cr. Its sector's average net profit growth for the last fiscal year was 91.1%.Quarterly Revenue,rose 14.88% YoY to ₹5,882.3 Cr. Its sector's average revenue growth YoY for the quarter was 16.15%.
Founded in 1983 to make world‑class healthcare accessible in India, Apollo Hospitals Enterprise Limited (AHEL) has grown into an integrated healthcare ecosystem spanning hospitals, retail health and diagnostics, digital health and large‑scale pharmacy distribution. The network includes 73 hospitals, 10,100+ beds, 13,000+ doctors, 2,900+ retail health centres and 6,600+ pharmacies; in FY 2025 Apollo served 7.38 million outpatients with an average length of stay of 3.3 days and 6,04,240 discharges. Its digital platform Apollo 24/7 provides virtual consultations, e‑pharmacy and remote care, complementing AI‑driven diagnostics and robotic‑assisted procedures across the system.
Apollo operates mainly in India, supported by international entities including Apollo Singapore Pte Ltd and Apollo Hospitals (UK) Ltd, which sit within the broader group structure. Key brands across the portfolio include Apollo 24/7 (digital health), Apollo Pharmacy, and retail health formats covering clinics, diagnostics, Spectra, Cradle, Sugar, Dental and Dialysis, integrated to improve continuity of care and outcomes.
Apollo reports three operating and reportable segments, plus an “Others” category.
Breakdown of Apollo Hospitals’ segment revenue for FY2025:
The Board approved a Composite Scheme of Arrangement (June 30, 2025) to demerge the omni‑channel pharmacy distribution and digital health platform (including Remote Telehealth) and the investment in Apollo HealthCo Limited, and to merge Keimed Private Limited, Apollo HealthCo’s omni‑channel pharmacy distribution and Apollo 24×7 digital platforms into a 100% subsidiary, Apollo HealthTech Limited (NewCo).
Shareholders of Apollo Hospitals Enterprise Limited (AHEL) would receive 195.2 NewCo shares for every 100 AHEL shares, with NewCo listing targeted in 18–21 months, subject to approvals and NCLT process around February 2026 .
During FY 2025, Apollo HealthCo Limited invested 7,250 million in Keimed Private Limited, strengthening the distribution platform pending completion of the proposed structure.
Capacity expansion remains a priority: the company highlights 10,100+ beds in FY 2025, with plans for 11,750+ by FY 2027 and 13,750+ beds approved through FY2030, and a network of 800+ telemedicine centres extending reach beyond metros. In retail pharmacy, the platform added 607 outlets in FY 2025 (net increase 596), continuing its footprint expansion across states through an omnichannel model that supports patient retention and private‑label cross‑sell.
Apollo operates hospitals and hospital‑based services, retail health and diagnostics, and a digital health and pharmacy distribution platform.
As of FY 2025, Apollo has 73 hospitals, 10,100+ beds, 13,000+ doctors, 2,900+ retail health centres and 6,600+ pharmacies .
The Board approved a Composite Scheme to create a listed omni‑channel pharmacy distribution and digital health leader (NewCo) by demerger and mergers, with a share swap of 195.2 NewCo shares for every 100 AHEL shares and a targeted listing in 18–21 months, subject to approvals .
